《HLT：新冠等重大传染病疫情：对社会和卫生经济的影响以及真实世界证据的产生和作用白皮书（2022）（37页）.pdf》由会员分享，可在线阅读，更多相关《HLT：新冠等重大传染病疫情：对社会和卫生经济的影响以及真实世界证据的产生和作用白皮书（2022）（37页）.pdf（37页珍藏版）》请在三个皮匠报告上搜索。

1、?COVID-19 and Pandemics:Influences to Social and Health Economy,and RWE Generation Copyright 2020 HLT All rights reserved.?COVID-19 and Pandemics:Influences to Social and Health Economy,and RWE Generation?2020年 3 HLT创新医疗解决案事业部 Copyright 2020 HLT All rights reserved.?1.?5?2.?6?2.1?6?2.1.1?6.2.1.2?7.2

2、.2?11?2.2.1?换?11.2.2.2?受?11.2.2.3?罩?12.2.2.4?德?12.3.?SARS?14?3.1?SARS?14?3.2?15?4.?17?4.1?SARS?17?4.1.1?17.4.1.2?17.4.1.3?分?18.4.1.4?预?忽?分?19.4.2?H1N1?20?4.2.1?H?N?分?20.4.2.2?德?德?H?N?类 20.4.2.3?德?德?H?N?21.4.2.4?预?忽?HIN?分?22.4.3?EBOV?22?4.3.1?22.4.3.2?德?德?类?23.4.3.3?24.4.3.4?预?忽?肛?24.4.4?COVID-19?25?

3、4.4.1?25.4.4.2?德?类 25.4.4.3?26.4.4.4 德?26.4.4.5?预?忽?分?27.5.?30?31Copyright 2020 HLT All rights reserved.1.?2019?2019-nCov?缺?克?SARS-CoV?MERS-CoV?COVID-?德?德?8?农?预?克?德?农?160?4?10糖?12:00?续?忽?农?续?忽?缺?预?WHO?德?PHEIC?点?2003?SARS?忽续?预?德?PHEIC?睛2009?H?N?2014?2018?2019?续?忽?类?忽?预?忽?点?熊腾滨?HLT?2020?3?Copyright 20

4、20 HLT All rights reserved.1.?2.?2.1?2.1.1?睛?1?2.1.1.1?睛?换?换?换?忽?纳?COVID-?续?换?睛?ICU?ECMO?换?睛?分?农?续?COVID-?农?忽?忽?续?忽?农?分?换?出?换?SARS?COVID-?忽?绪?换?睛?续?续?2.1.1.2?现?盲?换?换?/?换?续?剂?Copyright 2020 HLT All rights reserved.2.?德?2016?21?肛?21st Century Cures Act?德?肛?FD&C Act?505F(b)?预?Real World Evidence,RWE?“缺

5、?忽?”?肛?德?FDA?忽克?预?类?肛?2017-2018?FDA?预?肛?预?忽?预?/?糖?缺?德?德?预?2019?5?预?续?德?预?德?预?China Real World Data and Studies Alliance,ChinaREAL?预?预?续?预?/?缺?糖?2.1.2 宏观层?GDP?受盲?类?类?.?.?.?GDP?德?续?2020?GDP?滋忽6%?续?GDP?滋?危?出?危?性?2.1.2.2?分?分?农?缺?德?危?排?农?分?分?续?分?Copyright 2020 HLT All rights reserved.?忽?呈?受?德?农?6,7?1?GDP

6、?2020?德?分?2019?2?农?3?续?忽?德?熟?点?忽?罩?德?4?5?分?分?分?受?分?缺?分?肛?2020?6?分?6,7?1?COVID-?/?2?3?农?4?点?5?全?RT-PCR?NGS?6?盲?意?睛?盲?ECMO?盲纳?德?忽?农?分?德?分?Copyright 2020 HLT All rights reserved.?缺?1?AI?冲?绪缺忽?受?绪缺?分?2?忽?纳?危?受?纳?罩?农?罩?罩?3?4?CRO?CDMO?德CRO?绪缺?全?罩?农?CRO?CDMO忽?德?忽?缺?2.1.2.3?分?分?缺?滋?滋?缺?睛纳?意?2.1.2.4?1?分?分?To

7、B?缺?2?忽?忽?3?分?缺?受?分?危?意?4?Copyright 2020 HLT All rights reserved.?5?&?分?&?分?2.1.2.5?冲?农?农?缺?忽?冲?换?缺?缺?5G?冲?纳?农?排?2.1.2.6?O?O?忽续?滋?况?滋?2.1.2.7?O?O+?2003?+?2.1.2.8 受?受?2.1.2.9?意?农?缺?2.1.2.10?CEO?忽?2.1.2.11?Copyright 2020 HLT All rights reserved.?危?续?危?分?2.2?2.2.1?德?德?克?12?2.2.2?2.2.2.1?受?续?危?分?COVID-1

8、9?续忽?全?续?睛?ICU?ECMO?德?受?德?受?类?受?罩?受?德?受?受?受?罩?德?受?缺?172?2?19?2?2.2.2.2?受?忽?13?忽SARS?续-?SARS?类?14?H1N1?性?续?2.24?15,16?德?忽?忽?农?滋?忽?COVID-19?剂?WHO?2?11糖?续?COVID-19?18?17?忽?熟?忽?忽续?18?点?德?德?罩?Copyright 2020 HLT All rights reserved.WHO绪缺?点?危?续?COVID-19?忽?德?受?睛?分?受?2.2.2.3?受?9?2.2.3?“?”?绪缺?罩分?绪缺?2.2.4?德?点?

9、意?危?意?意?德?2.2.4.1?危?德?分?分?全?睛?盲纳?CT?ECMO?忽?糖续?+?点?类?糖续?+?点?德?续?忽?睛CT?CT?全?绪缺?绪缺?19?2.2.4.2?点?续?危?分?点?德?续?缺?点?农?纳?忽?Copyright 2020 HLT All rights reserved.?忽?农?缺?忽?忽?点?德?点?20,21?2.2.4.3?德?危?剂?罩?绪缺?罩?纳?忽?罩?忽绪缺?9?2.2.4.4?+?“?”?忽?纳?危?受?纳?“?”?“?”?罩?农?罩?罩?8?2.2.4.5?肛?危?盲?缺?绪缺?危?忽?意?睛?绪缺?危?9?绪缺德?点?点?点?点德?2

10、,12?Copyright 2020 HLT All rights reserved.3.SARS?3.1?SARS?Severe Acute Respiratory Syndrome?SARS?21?缺罩?德?全?缺?换?SARS?忽300-1000?换?忽300-1000?22?德?忽?换?忽120-180?23?德?SARS?德?GDP?3.1%24?忽?缺?农忽110?25?忽?SARS?农?分?忽?受?步?71?2003?SARS?性?175.44?22.36%26?2003?SARS缺?27?性?2.26?28?性?1.88?29忽?性?4?势?disability-adjuste

11、d-life-year?DALY?654.73?出?换?years-of-life-lost?YLL?1.5?兵?SARS?农?续?忽?SARS?忽?6?30?1?31?2?32?势?盲?势/?换?Hong-Jen Chang?SARS?SARS?纳?分?SARS?盲?盲?盲?23.9%?35.2%?16.7%?现?纳?33?Copyright 2020 HLT All rights reserved.3.SARS?分?纳?分?续?续?3.2?Ebola virus?EBOV?允?忽?预?World Health Organization,WHO?EBOV?4?Biosafety Level

12、4?SARS?3?34?缺?2014?2016?531.9?35?预?world bank?EBOV?36?2014-2015?28?6?3?19?德?GDP?滋?德?滋?农?分?30?60?缺?2015?GDP?8.5?9.4?4.8?农?德?德?忽克?6?GDP?2013?8.7?2014?0.7?2015?GDP?0.1?忽?4.0?2014?GDP?5.3?滋?0.8?2015?GDP?-21.5?德?全?德?2014?2015?GDP?19?10?5?EBOV?缺?37?滋?80%?5?40%?出?滋?睛?受盲?换?滋?分?EBOV?续?缺?德?缺?续?Elmahdawy?续?续?1

13、?类?续?ETUs?Ebola Treatment Units?续?盲?续?2?盲?续?3?续?4?盲?续?5?续?6?续?7?类?类?8?9?续?农?德2019?续?危?Copyright 2020 HLT All rights reserved.?缺?COVID-19?缺?点?续?类?德?意?德?类?德?兵?Copyright 2020 HLT All rights reserved.4.?4.1?SARS?4.1.1?Severe Acute Respiratory Syndrome,SARS?SARS?21?缺罩?德?全?全?,忽?,?SARS?全?忽?,?,?预?SARS?2002?

14、11?忽?德?忽2003?2?33?德?/?德?4.1.2?4.1.2.1?分?类?SARS?2002?11?2003?2?滋?2003?2?10糖?全?2003?4?17糖?忽?绪?类?3?预?忽?忽3?12糖?Copyright 2020 HLT All rights reserved.4.?预?3?15糖?“?”?4?4糖德?德?受?德?4.1.2.2?忽2003?4?17糖?忽?类?睛?1?德?德?2?6?意?类?SARS?21?15?SARS?14?绪?SARS?3?分?点?4?20?5?24?6?德?类?7?克?德?德?纳?点?忽?24?预?忽3?9?德?11?SARS?SARS?

15、肛?续?忽忽?熟德?德?德?德?忽?4.1.3?SARS?出?预?29?德?/?忽?德?忽?点?SARS?2003?6?全?德?2003?8?7?8322?出916?Copyright 2020 HLT All rights reserved.?11%?德?德?63.25%?出?20.83%?1?出?缺?WHO?SARS?预?分?忽2003?5?SARS?德?49%?2002?5?83%?17%?德?50%-78%?(ADB)?SARS?忽?换?590?德?换?179?德GDP?1.3%?德?换?120?GDP?7.6%?4.1.4?SARS?忽?类?类?2003?3?17糖?9?德?11?S

16、ARS?(?)?SARS?肛?续?糖?忽?预?Sun W?2003?4?10糖?5?12糖忽?272?Hon?忽2003?3?13糖?28糖?10?SARS?克?Loletta K-Y So?忽?肛?31?肛?11?肛?睛?点?1?17?13?忽?点?Copyright 2020 HLT All rights reserved.?4?忽?出?Zhang RL?49?29?）?20?）?忽?SARS?忽?危?点?忽?类?全?忽?R0?2.2-3.7?,?,?SARS?SARS-CoV?10.3%?60%?2.4?31.3?/1000?4.2?H1N1?4.2.1?H1N1?2009?H1N1?H

17、INI?忽?全?忽?意?农?全?,?H1N1?2009?3?4?德?德?H1N1?4?潜?WHO?克?H1N1?5?2009?5?H1N1?忽?德?2009?5?11糖?德?H1N1?2009?6?11糖?预?(WHO)?H1N1?WHO?40?缺?6?4.2.2?H1N1?忽?HIN1?德?CDC?全?类?（?）主动向世界卫组织（World Health Organization,WHO?报告甲型H?N?流感病例；?2?EOC）?3?类?4?H1N1?德?德?5?德?25%?6?出?Copyright 2020 HLT All rights reserved.?7?受?受?德CDC?类?FD

18、A农?类?罩?H1N1?分?分?罩?H1N1?德?忽续?类?睛?1?忽?绪?德?HIN1?德?类?2?HIN1?类?3?H1N1?肛?4?2009?7?8糖?H1N1?类?H1N1?5?2009?9?德?H1N1?德?忽?德?WHO?3?农?德?德?6?肛(2011?)?10?10?7?因?(2011?)?德德?德?德?4.2.3?H1N1?H1N1?预214?德?1.8?出?德?出?忽?德?H1N1?5-6?8-10?2?11?滋?2009?4?12糖?2010?4?10糖?德?6?出1.2469?2010?8?10糖?WHO?H1N1?德?2010?5?16糖?34?H1N1?出?2011

19、?1?16糖?德?H1N1?出?7?出16?2012?12?21糖?德?12?出648?全?德?类?续?Copyright 2020 HLT All rights reserved.?续?H1N1?类?类?续?德?缺?受?类?分?德?续?忽?忽?克?农?公?德?类?德?剂?肛农?H1N1?绪?潜?德?4.2.4?HIN1?忽?CDC?2009?H1N1?德?危?预?农?出?HIN1?全?全?睛?忽?纳?点?全?德忽?出?全?忽?H1N1?肛(2010?)?“?”农?HIN1?2009?H1N1?忽?德?5?预?剂?点?4.3?EBOV?4.3.1?EBOV?允?忽?WHO?EBOV?4?(Bi

20、osafety Level 4)?SARS?3?Copyright 2020 HLT All rights reserved.?1976?忽?全?德?缺?克?2014?2016?2014?8?8糖?WHO?德?PHEIC）?2016?3?29糖?PHEIC?28 616?11310?出?德?缺?2018?全?德?WHO忽2019?7?17糖?PHEIC?2020?2?4糖WHO?3429?2251?出?4.3.2?忽?德?德?类?4.3.2.1?2014?德?决?忽?类?德?忽?预?德?德?德?德?类全?忽?1?忽?德?2?盲?3?中国在2014年西疫情爆发以后制定了系列相关的应对措施，为我国

21、未来防范埃博拉病毒以及其他潜在传播病毒疫情事件起到了防范和警作。其中包括70：（1）度重视埃博拉病的防控作。（2）严格实施埃博拉病毒疾病国境检疫（3）积极参与联合国应对埃博拉病毒疾病的疫情动（4）及时研发实验室相关诊断试剂。4.3.2.1?2018年的埃博拉疫情爆发相对吸取往年疫情的经验，主要采取了以下应对措施71：（1）刚果共和国刚果民主共和国卫部在马建了战略协调中，并设有紧急动中（EOC），该中通过向马报告的较低政级别的紧急动中来监视动的执情况，并直接与卫区中的团队进联系；（2）平等机会委员会和刚果民主共和国卫部委员会（例如，监控疫苗接种以及葬礼）协调了多学科快速反应组的部署，以持受影响的

22、卫区；（3）通过发布每情况报告来加强交流和监督作。Copyright 2020 HLT All rights reserved.除此之外，全球针对多次爆发的埃博拉病毒所提议的系列预措施包括72：（1）发现疫情并迅速隔离病例；（2）病例相关接触员的跟踪调查；（3）泛的分布图和危地区的确定有助于进协调的疫情筛查作；（4）环形疫苗接种；（5）实验室诊断采GeneXpert(Cepheid)聚合酶链反应作为诊断具；（6）安全、有尊严的埋葬和；（7）风险沟通、社区参与和社会动员。4.3.3?忽2016?3?29糖PHEIC?28616?11310?出?2018?缺?2020?2?4糖?3429?2251

23、?出?德农?缺?忽?德?EVD?1,024?EVD?303?,?53.14?忽?,?2811?糖?性忽90?“?”?“?”?睛30?280?盲?225?4.3.4?忽?危?Kibuuka?忽2015?忽?1b?EBO?MAR?2009?2010?108?18-50?5?1?忽?0?4?8?模?忽?性?EBO?MAR?克?克?2017?Konde?忽?IFN?-1a?IFN-1a?EVD?2015?ETU?9?IFN-1a?忽?忽?21?睛?缺?17?绪?出?1.5?1.9?IFN-1a?忽?危?Halfmann?忽2019?2015-2016?忽?EBOV?187?睛132?30?续?ELIS

24、A?忽?绪?EBOV?危?Copyright 2020 HLT All rights reserved.?睛?忽?EBOV?危?。4.4?COVID-19?4.4.1?2019?(2019-nCov)?缺?克?SARS-CoV?MERS-CoV?SARS-CoV?75?-80?中国武汉地区约在2019年12开始发现新型冠状病毒?2020?1?10糖?41?全?睛?德?忽1?13糖?德?德?1?31糖?预?罩?“德?PHEIC?”?糖?剂忽?“?”?2020?2?10糖?德?40262?23589?3283?出?909?德?319?29?出1?4.4.2?缺?德?2020?1?25糖?点?忽?德

25、德?全?睛?克?忽?全?类?1?危?2?肛?5?肛?3?4?德?盲?盲?5?肛?6?盲?7?分?忽?类全?睛?Copyright 2020 HLT All rights reserved.?1?2?13?类?公?3?4?受?危?盲纳?糖?5?6?7?罩?类?续?德?农?缺?/?分?罩?纳?缺?忽?分?德?德?4.4.3?缺?忽?缺?全?缺?类?忽?德?忽?1?31糖?德?全?“?”?农?2?5糖?德?德?潜?绪?忽?“?”?2?7糖?忽缺?缺?忽?典?德?缺?剂?肛?授?德?典?忽?忽?忽?4.4.4?Copyright 2020 HLT All rights reserved.续?德?预?德

26、?德?类?绪?德?德?德德?睛?忽?预?4.4.5?忽?预?危?农?肛?危?忽?意?缺?预?忽?睛?1?忽?2020?1?2糖忽?41?=30?11?41?27?性?盲?6?出?5?势?4?2?1?565?糖续?德?德?危?糖续?忽?8?4?3?Kwok-Yung Yuen?模?全?忽?睛7?6?忽2019?12?29糖?2020?1?4糖?5?睛?续?续?4?1?26糖?德?/德?德?危?5?2019?2020?1?缺?30?2019?德?熟德?GISAID?5?1?31糖?NEJM?忽?德?忽?熟?Gilead?忽?Remdesivir?熟?6?2?1糖?忽?农忽?;?农?COVID-19

27、?忽?Copyright 2020 HLT All rights reserved.?7?德?2糖?忽?德?48?8?忽?SARS-CoV?MERS-CoV?预?续?忽?德?肛?2020?2?6糖?预?Clark D Russell?Jonathan E Millar?J Kenneth Baillie?忽Lancet?2019-nCoV所致的肺损伤。（source：Clark D Russell，Jonathan E Millar，J Kenneth Baillie：Clinical evidence does not support corticosteroid treatment for

28、?-nCoV lung injury，DOI:https:/doi.org/?.?/S?-?(?)?-?）?9?德?农?纳?农?忽?危?忽?预?忽?1?糖?忽2020?1?2糖?RT-PCR?41?COVID-19?模?危?续?26?COVID-19?ICU?出?农?绪缺?危?2?缺?糖续?Natalie M.Linton?1?25糖?1287?R?COVID-19?95%CI?2-9?糖?9?3?德?(?睛?425?COVID-19?COVID-19?性?59?56%?忽2020?1?1糖?55%?忽?8.6%?性?5.2?忽?2019-nCoV?7.4?2020?1?COVID-19?R0

29、?2.2?性?2.2?12?Copyright 2020 HLT All rights reserved.?4?缺?德?全?1?1糖?1?20糖?99?绪?2019-nCov?全?忽?点?出?5?续?2020?1?29糖31?/?552?1099?COVID-19 ARD?47.0?41.90%?1.18%?31.30%?71.80%?缺?(87.9%)?(67.7%)?3.0?(?0?24.0?)?82.1%?忽?2019-nCoV?忽?模?预?公?危?1?Gabriel Leung?Joseph Wu?1?25?肛?续?R0?2.13?1.92?2.31?忽 6.2?类?忽4?5?忽6?7

30、?2?德?Lancaster?Jonathan M Read?COVID-19?2019-nCov?transmissibility?SARS?MERS?忽?SARS?R0?3.6-4.0?5.1%?94.9%?绪?3?缺?德?R.N.Thompson?1?24糖?47?COVID-19?德?德?0.37?忽?类?0.005?点?德?类?4?忽?忽?2019-nCov?续?268(95%CrI 247-286)?2020?1?25糖?75815?(95%CrI )?64?(95%CrI 58-71)?忽?461?(95%CrI 227-805)?113?(57-193)

31、?98?(49-168)?111?(56-191)?80?(40-139)?COVID-19?忽德?忽?德?全?1-2?Copyright 2020 HLT All rights reserved.5.?全球经济体化进程的推进和分的细化使各个国家和地区在突发规模疫情时都很难独善其，因此针对我国现阶段基本情况深研究突发规模疫情和经济之间的关系，以及真实世界证据的产和积累，有重要的现实意义。在对抗疫情的过程中我们可以看到，新型冠状病毒在内的烈性传染病疫情都进展迅速，类付出了艰苦的努来应对这场场没有硝烟的战争。在艰巨的临床诊疗和公共卫管理过程中，量的真实世界证据和科学理论以及经验教训得以产、积累和沉

32、淀。类通过对真实世界数据进细致的研究分析，逐步加深了对于各次疫情的认知，也为制定更为效的应对策略以及卫政策提供了有持，并使类在不断的与疾病做争的过程中积累了愈加丰富的宝贵经验。另外，规模疫情（包括COVID-19、SARA以及EBOV等）短期内会对经济造成巨冲击，影响主要集中在第三产业，随着我国经济的不断发展，第三产业在经济结构中的重不断上升，对突发规模疫情的敏感性进步增强。其次，虽然规模疫情期间消毒品、医药等业的消费刺激宏观上形成了种替代性补偿，但这种补偿相对于损失来讲起到的作很。再次，我国幅员辽阔、众多、内需强劲，因此即便短期内进出贸易受到明显影响，但国内市场仍然可以维持整体经济的正常运转

33、，抗冲击能较强。最后，虽然规模疫情对经济的冲击很，但类很快就能找到对抗的法，从长期来讲类必将战胜不断出现的挑战，因此对长远的经济形势和消费信影响没有短期冲击。突发规模疫情防控能同经济发展之间是相互促进的关系，发展经济能够提国家综合实，在应对规模疫情时能够有充的、物、财投其中，较的疾病预防控制平也能够更好地抵御规模突发疫情的侵袭，因此促进经济和疫情防控能的协调发展能有效降低突发规模疫情的经济影响。在突发规模疫情暴发后，政府应从增加投、刺激需求、减免主要受影响业的税收等采取积极措施，维护经济正常运，将突发规模疫情造成的损失降到最低。Copyright 2020 HLT All rights res

34、erved.5.?1.张，祖正，晴许，等.突发规模疫情对经济的影响分析J.军事医学,2014,38(2):124-128.2.健康时报.抗击新冠肺炎疫情下，公共卫体系的应对与挑战Z.2020.?.张涛，蔡华，顾宝柯，等.上海市甲型H?N?流感患者经济负担估计J.中国卫经济,?,?(?):?-?.4.BCG.新型冠状病毒疫情影响R.2020.5.思齐俱乐部.新冠疫情对医药业的影响及药企未来转型之路Z.2020.?.?.?德?Z.2020.7.毕马威KPMG.确保企业连续性管理能7：新型冠状病毒疫情对中国医药业影响初探Z.2020.?.?.?德?R.2020.?.?预.BCG宿?6?Z.2020.

35、10.环境与发展经济学.严重疫情的长期影响：住房与贫困Z.2020.?.?.?CEO?忽?R.2020.?.?德?.?德?克?Z.2020.?.?.?续-?J.?德?,2005,10(4):471-474.?.赵根明，陈健，张涛，等.上海市中学接种甲型h?n?流性感冒疫苗的成本-效益分析J.中华预防医学杂志,?,?(?):?-?.?.Baguelin M,Van Hoek A J,Jit M,et al.Vaccination against pandemic in?uenza A/H?N?v in England:a real-time economic evaluationJ.Vaccin

36、e,?,?(?):?-?.Copyright 2020 HLT All rights reserved.?.杨东平.流性感冒的疾病负担和疫苗/药物预防的经济效益研究J.职业与健康,?,?(?):?-?.?.WHO.WHO Director-Generals remarks at the media brie?ng on?-nCoV on?February?Z.?.?.?.?熟?Z.2020.?.?.?分?分?R.2020.?.?.?J.?,2020(1):273.?.?攀?.?J.?,2020(1):282.?.Smith.Responding to global infectious dis

37、ease outbreaks:lessons from SARS on the role of risk perception,communication and managementJ.Soc Sci Med,?,?(?):?-?.?.Wishnick E.Dilemmas of securitization and health risk management in the Peoples Republic of China:The cases of SARS and avian in?uenzaJ.Health Policy Plann,?,?(?):?-?.?.R K M,D S R.

38、The economic impact of SARS:How does the reality match the predictions?J.Health Policy,?,?(?):?.?.Du L,Luo B,Wang J,et al.Study on Social Burden of ASRS in GuangzhouJ.Chinese Journal Of Public Health Mangement,?,?(?):?-?.?.Zeng B,Carter R W,De Lacy T.Short-term perturbations and tourism e?ects:The c

39、ase of SARS in ChinaJ.Current Issues in Tourism,?,?(?):?-?.?.?.?J.?,2003(7):3-4.?.肖峰，陈博，武阳丰，等.北京市SARS临床诊断病例住院费及影响因素分析J.中华流病学杂志,?,?(?):?-?.?.王建华，杜琳，罗不凡，等.州市SARS病例经济负担研究J.华南预防医学,?,?(?):?-?.Copyright 2020 HLT All rights reserved.?.S H D,M J G,T W K,et al.Impact of severe acute respiratory syndrome(SARS

40、)on pulmonary function,functional capacity and quality of life in a cohort of survivorsJ.Chest,?,?(?):?-?.?.C O K,K N W,U L S,et al.?-Year Pulmonary Function and Health Status in Survivors of Severe Acute Respiratory SyndromeJ.Chest,?,?(?):?-?.?.C N J,O F W K,G S S N,et al.The long-term impact of se

41、vere acute respiratory syndrome on pulmonary function,exercise capacity and health statusJ.Respirology,?,?(?):?-?.?.J C H,N H,H L C,et al.The Impact of the SARS Epidemic on the Utilization of Medical Services:SARS and the Fear of SARSJ.Am J Public Health,?,?(?):?-?.?.乔春霞，沈倍奋，吕明.抗埃博拉病毒治疗性抗体研究进展J.国际药学

42、研究杂志,?,?(?):?-?.?.World Health OrganizationZ.?.Bank T W.?-?West Africa Ebola Crisis:Impact UpdateR.,?.?.Jw E,C C,P N,et al.The health impact of the?-?Ebola outbreakJ.Public Health,?,?:?-?.?.Lam W K,Zhong N S,Tan W C.Overview on SARS in Asia and the WorldJ.Respirology,?,?.?.范学,云铸.严重急性呼吸综合征?典型性肺炎讨论J.中

43、国现代医学杂志,?(?).?.Drosten C,Gnther S,Preiser W,van der Werf S,Brodt H R,Becker S et al.Identi?cation of a novel coronavirus in patients with severe acute respiratory syndrome.New England Journal of Medicine,?,?:?-?.?.Peiris JSM,Lai ST,Poon LLM,Guan Y,Yam LYC,W Lim W et al.and SARS study group.Coronavir

44、us as a possible cause of severe acute respiratory syndrome.Lancet,?,?:?.Copyright 2020 HLT All rights reserved.?.Peiris JSM,Lai ST,Poon LLM,Guan Y,Yam LYC,W Lim W et al.and SARS study group.Coronavirus as a possible cause of severe acute respiratory syndrome.Lancet,?,?:?.?.Antia R,Rogoes RR,Koella

45、JC,Bergstrom CT.The role of evolution in the emergence of infectious diseases.Nature,?,?:?-?.?.Retrospective analysis for?rst-visiting case data of?SARS inpatients in Peking University Third HospitalJ.Journal of Beijing Medical University,?.?.So K Y,Lau A C,Yam L Y,et al.Development of a standard tr

46、eatment protocol for severe acute respiratory syndromeJ.Lancet(North American Edition),?,?(?):?-?.?.Rui-Lin Z,Qiang J,Bao-Guo W.Controlled Clinical study on?Patients of SARS Treated by Integrative Chinese and Western MedicineJ.Chinese Journal of Integrated Traditional and Western Medicine,?,?(?):?.?

47、.Riley,S.Transmission Dynamics of the Etiological Agent of SARS in Hong Kong:Impact of Public Health InterventionsJ.Science,?,?(?):?-?.?.Marc,Lipsitch,Ted,et al.Transmission dynamics and control of severe acute respiratory syndrome.J.Science(New York,N.Y.),?.?.CDC.(?).Swine-origin in?uenza A(H?N?)vi

48、rus infections in a school-New York City,April?.MMWR.Morbidity and mortality weekly report,?(?),?.?.WHO.Preliminary information important for understanding the evolving situation:novel in?uenza A(H?N?)brie?ng note?.Geneva,Switzerland:World Health Organization;?.?.刘宇鹏.(?).甲型h?n?流感流?周年记.医学与哲学(临床决策论坛版)

49、(?),?-?.?.WHO.(?).New in?uenza A(H?N?)virus:global epidemiological situation,June?.Weekly Epidemiological Record=Relev pidmiologique hebdomadaire,?(?),?-?.?.CDC.(?).?H?N?Pandemic Timeline.Available at:https:/www.cdc.gov/?u/pandemic-resources/?-pandemic-timeline.html Copyright 2020 HLT All rights res

50、erved.?.孔鹏,孟庆跃,&贾莉英.(?).我国甲型h?n?流感防控策略的评析及选择.医学与哲学(临床决策论坛版)(?),?-?.?.中华共和国卫部.(?).卫部关于将甲型H?N?流感(原称感染猪流感)纳中华共和国传染病防治法和中华共和国国境卫检疫法管理的公告(?年第?号).http:/ at:https:/www.cdc.gov/?u/pandemic-resources/?-h?n?-pandemic.html?.WHO.(?).WHO recommendations for the post-pandemic period.Retrieved October.?.中国国家流感中.(?

51、).?第?周流感周报.http:/ down.php?downid=?.?.Pasquini-Descomps,H.,Brender,N.,&Maradan,D.(?).Value for money in H?N?in?uenza:A Systematic review of the cost-e?ectiveness of pandemic interventions.Value in Health,?(?),?-?.?.陈和平.(?).美国应对甲型h?n?流感的经验及防控建议.全球科技经济瞭望(?),?-?.?.占成.(?).重视和总结我国临床诊治甲型h?n?流感的经验.中国呼吸与危重监

52、护杂志,?(?),?-?.?.Siston,A.M.,et al.(?).Pandemic?in?uenza A(H?N?)virus illness among pregnant women in the United States.Jama,?(?),?-?.?.Fraser,C.,et al.(?).Pandemic potential of a strain of in?uenza A(H?N?):early?ndings.science,?(?),?-?.?.?,?,&?.(2009).?h1n1?.?德德?(04),36-38+42.Copyright 2020 HLT All r

53、ights reserved.?.徐喜卿,&李顺平.(?).我国甲型h?n?流感疫苗免疫效果评估系统综述.实预防医学,v.?(?),?-?.?.乔春霞,沈倍奋,吕明.抗埃博拉病毒治疗性抗体研究进展J.国际药学研究杂志,?,?(?):?-?.?.World Health Organization https:/www.who.int/csr/disease/ebola/en/?.?,?,?点.?-?德忽?J.?,2015(1?):1-5.?.Aruna A,Mbala P,Minikulu L,et al.Ebola Virus Disease Outbreak-Democratic Repub

54、lic of the Congo,August?-November?.MMWR Morb Mortal Wkly Rep.?;?(?):?.Published?Dec?.doi:?.?/mmwr.mm?a?.Inungu J,Iheduru-Anderson K,Odio OJ.Recurrent Ebolavirus disease in the Democratic Republic of Congo:update and challenges.AIMS Public Health.?;?(?):?.Published?Nov?.?.?,?,?,et al.?德?J.?德?,2019(5)

55、:423-427.?.Kibuuka H,Berkowitz NM,Millard M,et al.Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults:a phase?b,randomised,double-blind,placebo-controlled clinical trial.Lancet.?;?(?):?.?.Konde MK,Baker

56、DP,Traore FA,et al.Interferon-1a for the treatment of Ebola virus disease:A historically controlled,single-arm proof-of-concept trial published correction appears in PLoS One.?Apr?;?(?):e?.PLoS One.?;?(?):e?.Published?Feb?.?.Halfmann PJ,Eisfeld AJ,Watanabe T,et al.Serological analysis of Ebola virus

57、 survivors and close contacts in Sierra Leone:A cross-sectional study.PLoS Negl Trop Dis.?;?(?):e?.Published?Aug?.?.?年?，新型冠状病毒?-nCoV持续流对全球健康的威胁?中国武汉市?新型冠状病毒的最新暴发情况（献解读陈语熙）Hui DS,E IA,Madani TA,et al.The continuing?-nCoV epidemic threat of novel coronaviruses to global health-The latest?novel coronav

58、irus outbreak in Wuhan,ChinaJ.Copyright 2020 HLT All rights reserved.?.?德?德?德糖?.Huang,C.,Wang,Y.,Li,X.,Ren,L.,Zhao,J.,Hu,Y.,.Cao,B.:Clinical features of patients infected with?novel coronavirus in Wuhan,China.The Lancet.https:/doi.org/?.?/S?-?(?)?-?.Kupferschmidt,K.,Cohen,J.:Will novel virus go pand

59、emic or be contained?Science.?,?(?).https:/doi.org/?.?/science.?.?.?.?年?，次发现了传的证据（献解读Simo Du）Chan,J.F.-W.,Yuan,S.,Kok,K.-H.,To,K.K.-W.,Chu,H.,Yang,J.,.Yuen,K.-Y.:A familial cluster of pneumonia associated with the?novel coronavirus indicating person-to-person transmission:a study of a family cluster

60、.The Lancet.https:/doi.org/?.?/S?-?(?)?-?.Michelle L.Holshue et al.,(?),First Case of?Novel Coronavirus in the United States,NEJM,DOI:?.?/NEJMoa?.?年?，新冠病毒可能存在新传染途径Zhang,H.,Kang,Z.,Gong,H.,et al.:The digestive system is a potential route of?-nCov infection:a bioinformatics analysis based on single-ce

61、ll transcriptomes.?.Linton,N.M.,Kobayashi,T.,Yang,Y.,et al.:Epidemiological characteristics of novel coronavirus infection:A statistical analysis of publicly available case data.medRxiv.?.?.?.?(?).?.Li,Q.,Guan,X.,Wu,P.,et al.:Early Transmission Dynamics in Wuhan,China,of Novel Coronavirus?Infected P

62、neumonia.New England Journal of Medicine.(?).?.Chen,N.,Zhou,M.,Dong,X.,et al.:Epidemiological and clinical characteristics of?cases of?novel coronavirus pneumonia in Wuhan,China:a descriptive study.The Lancet.?.Wei-jie Guan,Zheng-yi Ni,Yu Hu,etc.：Clinical characteristics of?novel coronavirus infecti

63、on in China.?.Professors Gabriel Leung,Joseph Wu.Real-time nowcast and forecast on the extent of the Wuhan CoV outbreak,domestic and international spread.Copyright 2020 HLT All rights reserved.?.Read,J.M.,Bridgen,J.R.,Cummings,D.A.,Ho,A.,Jewell,C.P.:Novel coronavirus?-nCoV:early estimation of epidem

64、iological parameters and epidemic predictions.medRxiv.?.?.?.?(?).?.Thompson,R.N.:?-?Wuhan coronavirus outbreak:Intense surveillance is vital for preventing sustained transmission in new locations.bioRxiv.?.?.?.?(?).?.Wu,J.T.,Leung,K.,Leung,G.M.:Nowcasting and forecasting the potential domestic and international spread of the?-nCoV outbreak originating in Wuhan,China:a modelling study.The Lancet.Copyright 2020 HLT All rights reserved.